Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
10
×
life sciences
national blog main
new york blog main
new york top stories
10
×
san francisco blog main
san francisco top stories
clinical trials
boston blog main
boston top stories
national
national top stories
raleigh-durham blog main
raleigh-durham top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
cancer
cancer immunotherapy
eli lilly
fda
deals
investing
medical device
startups
medicare
merck
migraine
pfizer
What
companies
10
×
bio
drug
ipo
life
roundup
science
week
new
biotech
street
wall
approval
days
fda
hasn’t
haul
ipos
latest
leading
led
migraine
momentum
nash
news
price
public
raised
satsuma
slowed
springworks
therapeutics
therapies
welcomed
year
activity
alzheimer’s
approved
arena’s
arguments
Language
unset
Current search:
biotech
×
companies
×
" new york top stories "
×
@xconomy.com
3 years ago
Two Days, Six IPOs, and $1B Raised for Biotech Research & More
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
SpringWorks and Satsuma Boost This Week’s Biotech IPO Haul to $595M
@xconomy.com
4 years ago
Pfizer Spinout SpringWorks, Migraine Drug Firm Satsuma Prep IPOs
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More
@xconomy.com
5 years ago
IPO Wave Rolls On as Five Life Science Firms Haul in $651M